Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects

Bibliography

• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26
   PubMed Web of Science ®Google Scholar
• Hauss DJ. Oral lipid-based formulations enhancing the bioavailability of poorly water-soluble drugs. Informa Healthcare USA, Inc; New-York: 2007
   Google Scholar
• Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413-20
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47(2-3):165-96
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58(3):173-82
   PubMed Web of Science ®Google Scholar
• Porter CJ, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008;60(6):673-91
   PubMed Web of Science ®Google Scholar
• Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995;12(11):1561-72
   PubMed Web of Science ®Google Scholar
• Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res 1989;6(1):40-3
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Amidon GL, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996;13(12):1838-45
   PubMed Web of Science ®Google Scholar
• Bekerman T, Golenser J, Domb A. Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci 2004;93(5):1264-70
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm 2009;35(12):1479-86
   PubMed Web of Science ®Google Scholar
• Thomas K, Koelwel C, Machei U, et al. Three generations of cyclosporine a formulations: an in vitro comparison. Drug Dev Ind Pharm 2005;31(4-5):357-66
   PubMed Web of Science ®Google Scholar
• Larsen AT, Ohlsson AG, Polentarutti B, et al. Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci 2013;48(1-2):339-50
   PubMed Web of Science ®Google Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47(1):3-19
   PubMed Web of Science ®Google Scholar
• Gershanik T, Haltner E, Lehr CM, et al. Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. Int J Pharm 2000;211(1-2):29-36
   PubMedGoogle Scholar
• Corbo DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci 1990;79(3):202-6
   PubMed Web of Science ®Google Scholar
• Gershanik T, Benita S. Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone. Pharm Dev Technol 1996;1(2):147-57
   PubMedGoogle Scholar
• Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000;50(1):179-88
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6(3):231-48
   PubMed Web of Science ®Google Scholar
• Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997;25(1):103-28
   Web of Science ®Google Scholar
• Carey MC, Small DM, Bliss CM. Lipid digestion and absorption. Annu Rev Physiol 1983;45:651-77
   PubMed Web of Science ®Google Scholar
• Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. J Young Pharm 2011;3(1):4-8
   PubMedGoogle Scholar
• Basalious EB, Shawky N, Badr-Eldin SM. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm 2010;391(1-2):203-11
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Sallee VL, Wilson FA. Unstirred water layers and absorption across the intestinal mucosa. Gastroenterology 1971;61(6):932-4
   PubMed Web of Science ®Google Scholar
• Wilson FA, Sallee VL, Dietschy JM. Unstirred water layers in intestine: rate determinant of fatty acid absorption from micellar solutions. Science 1971;174(13):1031-3
   PubMedGoogle Scholar
• Dimitrijevic D, Shaw AJ, Florence AT. Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. J Pharm Pharmacol 2000;52(2):157-62
   PubMed Web of Science ®Google Scholar
• Quan YS, Hattori K, Lundborg E, et al. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol Pharm Bull 1998;21(6):615-20
   PubMed Web of Science ®Google Scholar
• Koga K, Ohyashiki T, Murakami M, et al. Modification of ceftibuten transport by the addition of non-ionic surfactants. Eur J Pharm Biopharm 2000;49(1):17-25
   PubMed Web of Science ®Google Scholar
• Dudeja PK, Anderson KM, Harris JS, et al. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 1995;319(1):309-15
   PubMed Web of Science ®Google Scholar
• Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007;4(3):465-74
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84(21):7735-8
   PubMed Web of Science ®Google Scholar
• Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48(7):1926-9
   PubMed Web of Science ®Google Scholar
• Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992;66(1):62-8
   PubMed Web of Science ®Google Scholar
• Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996;13(4):528-34
   PubMed Web of Science ®Google Scholar
• Chen ML. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv Drug Deliv Rev 2008;60(6):768-77
   PubMed Web of Science ®Google Scholar
• Katneni K, Charman SA, Porter CJ. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci 2007;96(2):280-93
   PubMed Web of Science ®Google Scholar
• Zhang H, Yao M, Morrison RA, et al. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 2003;26(9):768-72
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13(3):129-34
   PubMed Web of Science ®Google Scholar
• Trausch B, Oertel R, Richter K, et al. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 1995;16(5):403-14
   PubMed Web of Science ®Google Scholar
• Elgart A, Cherniakov I, Aldouby Y, et al. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res 2013;30(12):3029-44
   PubMed Web of Science ®Google Scholar
• Benet LZ. Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol 2010;106(3):162-7
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008;38(7-8):778-801
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71(1):11-20
   PubMed Web of Science ®Google Scholar
• Engel A, Oswald S, Siegmund W, et al. Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm 2012;9(9):2577-81
   PubMedGoogle Scholar
• Peters WH, Kremers PG. Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol 1989;38(9):1535-8
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23
   PubMed Web of Science ®Google Scholar
• de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990;253(1):387-94
   PubMed Web of Science ®Google Scholar
• Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90(5):1871-8
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
   PubMed Web of Science ®Google Scholar
• Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80(4):1029-36
   PubMed Web of Science ®Google Scholar
• Benet LZ, Wu CY, Hebert MF, et al. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Release 1996;39:139-43
   Web of Science ®Google Scholar
• Komura H, Iwaki M. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev 2011;43(4):476-98
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2008;97(5):1775-800
   PubMed Web of Science ®Google Scholar
• Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 2006;58(9):1183-91
   PubMed Web of Science ®Google Scholar
• Ren X, Mao X, Si L, et al. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm 2008;70(1):279-88
   PubMed Web of Science ®Google Scholar
• Ren X, Mao X, Cao L, et al. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur J Pharm Sci 2009;36(4-5):401-11
   PubMed Web of Science ®Google Scholar
• CM OD. Anatomy and physiology of the lymphatics. In: William N, Charman VJS, editors. Lymphatic transport of drugs. CRC Press, Inc; Boka Raton, FL: 1992
   Google Scholar
• Cohen DE, Armstrong EJ. Biochemistry and physiology of cholesterol and lipoprotein metabolism. In: Golan DE, Tasjian AH, Armstrong EJ, Armstrong AW, editors. Principles of pharmacology. 3rd edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2011
   Google Scholar
• O’Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002;15(5):405-15
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50(1-2):61-80
   PubMed Web of Science ®Google Scholar
• Holm R, Porter CJ, Müllertz A, et al. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm Res 2002;19(9):1354-61
   PubMed Web of Science ®Google Scholar
• Khoo SM, Shackleford DM, Porter CJ, et al. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res 2003;20(9):1460-5
   PubMed Web of Science ®Google Scholar
• Seeballuck F, Lawless E, Ashford MB, et al. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res 2004;21(12):2320-6
   PubMed Web of Science ®Google Scholar
• Lind ML, Jacobsen J, Holm R, et al. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci 2008;35(3):211-18
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006;29(3-4):278-87
   PubMed Web of Science ®Google Scholar
• Boyd M, Risovic V, Jull P, et al. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat. J Pharmacol Toxicol Methods 2004;49(2):115-20
   PubMedGoogle Scholar
• Khoo SM, Edwards GA, Porter CJ, et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci 2001;90(10):1599-607
   PubMed Web of Science ®Google Scholar
• Edwards GA, Porter CJ, Caliph SM, et al. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev 2001;50(1-2):45-60
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. 2007;32(1):24-32
   Google Scholar
• Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 2005;26(5):394-404
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Fanous J, Qadri B, et al. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J Pharm Pharmacol 2009;61(1):31-9
   PubMed Web of Science ®Google Scholar
• Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 1998;87(2):164-9
   PubMed Web of Science ®Google Scholar
• Wu H, Zhou A, Lu C, et al. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems. Eur J Pharm Sci 2011;42(4):348-53
   PubMed Web of Science ®Google Scholar
• Nielsen FS, Petersen KB, Mullertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur J Pharm Biopharm 2008;69(2):553-62
   PubMed Web of Science ®Google Scholar
• Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994;11(1):151-5
   PubMed Web of Science ®Google Scholar
• Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54(6):925-75
   PubMed Web of Science ®Google Scholar
• Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc 1999;31(6):2203-5
   PubMed Web of Science ®Google Scholar
• Shimomura M, Masuda S, Saito H, et al. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res 2002;103(2):215-22
   PubMed Web of Science ®Google Scholar
• Elgart A, Cherniakov I, Aldouby Y, et al. Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chem Phys Lipids 2012;165(4):438-53
   PubMed Web of Science ®Google Scholar
• Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 2005;5(2):79-83
   PubMed Web of Science ®Google Scholar
• Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000;49(4):373-8
   PubMed Web of Science ®Google Scholar
• Gupta SK, Manfro RC, Tomlanovich SJ, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990;30(7):643-53
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58(5):492-7
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22(1):11-23
   PubMed Web of Science ®Google Scholar
• Arida AI, Al-Tabakha MM, Hamoury HA. Improving the high variable bioavailability of griseofulvin by SEDDS. Chem Pharm Bull (Tokyo) 2007;55(12):1713-19
   PubMed Web of Science ®Google Scholar
• Ofokansi KC, Chukwu KI, Ugwuanyi SI. The use of liquid self-microemulsifying drug delivery systems based on peanut oil/tween 80 in the delivery of griseofulvin. Drug Dev Ind Pharm 2009;35(2):185-91
   PubMed Web of Science ®Google Scholar
• Taha E, Ghorab D, Zaghloul AA. Bioavailability assessment of vitamin A self-nanoemulsified drug delivery systems in rats: a comparative study. Med Princ Pract 2007;16(5):355-9
   PubMed Web of Science ®Google Scholar
• Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11(2):301-4
   PubMed Web of Science ®Google Scholar
• Borhade V, Nair H, Hegde D. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech 2008;9(1):13-21
   PubMed Web of Science ®Google Scholar
• Abdalla A, Klein S, Mader K. A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets. Eur J Pharm Sci 2008;35(5):457-64
   PubMed Web of Science ®Google Scholar
• Cuine JF, McEvoy CL, Charman WN, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci 2008;97(2):995-1012
   PubMed Web of Science ®Google Scholar
• Zhou L, Naraharisetti SB, Liu L, et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010;31(4):228-42
   PubMed Web of Science ®Google Scholar
• Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 2009;98(10):3582-95
   PubMed Web of Science ®Google Scholar
• Liu H, Shang K, Liu W, et al. Improved oral bioavailability of glyburide by a self-nanoemulsifying drug delivery system. J Microencapsul 2014;31(3):277-83
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS. Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. Expert Opin Drug Deliv 2014;11(7):1023-32
   PubMed Web of Science ®Google Scholar
• Chopra M, Nayak UY, Gurram AK, et al. Formulation, characterization and In vivo evaluation of self-nanoemulsifying drug delivery system for oral delivery of valsartan. Cur Nutr Food Sci 2014;10(2):263-70
   Google Scholar
• Khan AW, Kotta S, Ansari SH, et al. Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: design, characterization, in vitro and in vivo evaluation. Drug Deliv 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ghai D, Sinha VR. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker talinolol. Nanomedicine 2012;8(5):618-26
   PubMed Web of Science ®Google Scholar
• Abdelbary G, Amin M, Salah S. Self nano-emulsifying simvastatin based tablets: design and in vitro/in vivo evaluation. Pharm Dev Technol 2013;18(6):1294-304
   PubMed Web of Science ®Google Scholar